Oxford Biomedica Provides FDA Response, Update On TroVax
Oxford BioMedica has received final comments following the FDA’s review of the phase-III TRIST study of TroVax in renal cancer, and the proposed clinical development outline. FDA acknowledged
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).